Daré Bioscience, Inc. (NASDAQ:DARE) Sees Large Growth in Short Interest

by · The Cerbat Gem

Daré Bioscience, Inc. (NASDAQ:DARE – Get Free Report) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 86,600 shares, a growth of 50.9% from the December 15th total of 57,400 shares. Based on an average daily volume of 50,200 shares, the short-interest ratio is presently 1.7 days. Currently, 1.0% of the company’s stock are short sold.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC lifted its position in Daré Bioscience, Inc. (NASDAQ:DARE – Free Report) by 2.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned about 9.25% of Daré Bioscience worth $262,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 6.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Daré Bioscience in a report on Tuesday, December 17th.

Read Our Latest Report on Daré Bioscience

Daré Bioscience Stock Performance

DARE traded up $0.01 on Friday, hitting $3.34. 11,893 shares of the company were exchanged, compared to its average volume of 22,963. The stock’s fifty day moving average is $3.30 and its 200-day moving average is $3.42. Daré Bioscience has a 12 month low of $2.67 and a 12 month high of $7.56. The company has a market cap of $29.06 million, a PE ratio of -5.65 and a beta of 1.28.

About Daré Bioscience

(Get Free Report)

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.

Read More